Merck & Co Inc (NYSE: MRK) – Suitable For Long Term Buy?

Currently, there are 2.53B common shares owned by the public and among those 2.53B shares have been available to trade.

The company’s stock has a 5-day price change of 6.74% and 22.20% over the past three months. MRK shares are trading 21.03% year to date (YTD), with the 12-month market performance up to 25.04% higher. It has a 12-month low price of $99.14 and touched a high of $133.10 over the same period. MRK has an average intraday trading volume of 8.69 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.44%, 6.17%, and 18.44% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of Merck & Co Inc (NYSE: MRK) shares accounts for 78.69% of the company’s 2.53B shares outstanding.

It has a market capitalization of $334.18B and a beta (3y monthly) value of 0.39. The stock’s trailing 12-month PE ratio is 998.11, while the earnings-per-share (ttm) stands at $0.13. The company has a PEG of 14.77 and a Quick Ratio of 1.00 with the debt-to-equity ratio at 0.97. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.36% over the week and 1.66% over the month.

Analysts forecast that Merck & Co Inc (MRK) will achieve an EPS of $2.05 for the current quarter, $2.02 for the next quarter and $9.77 for 2025. The lowest estimate earnings-per-share for the quarter is $1.78 while analysts give the company a high EPS estimate of $2.25. Comparatively, EPS for the current quarter was $1.4 a year ago. Earnings per share for the fiscal year are expected to increase by 468.66%, and 13.76% over the next financial year. EPS should grow at an annualized rate of 67.56% over the next five years, compared to -42.70% over the past 5-year period.

Looking at the support for the MRK, a number of firms have released research notes about the stock. Societe Generale stated their Sell rating for the stock in a research note on March 11, 2024, with the firm’s price target at $104. TD Cowen coverage for the Merck & Co Inc (MRK) stock in a research note released on January 04, 2024 offered a Outperform rating with a price target of $135. Deutsche Bank was of a view on November 09, 2023 that the stock is Buy, while BMO Capital Markets gave the stock Outperform rating on October 27, 2023, issuing a price target of $132. UBS on their part issued Buy rating on October 20, 2023.

Most Popular

Related Posts